Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patientderived GBM tumor cells

Amanda Tivnan, Tatjana Heilinger, Joanne M. Ramsey, Gemma O'Connor, Jenny L. Pokorny, Jann N Sarkaria, Brett W. Stringer, Bryan W. Day, Andrew W. Boyd, Ella L. Kim, Holger N. Lode, Sally Ann Cryan, Jochen H M Prehn

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aromatase is a critical enzyme in the irreversible conversion of androgens to oestrogens, with inhibition used clinically in hormone-dependent malignancies. We tested the hypothesis that targeted aromatase inhibition in an aggressive brain cancer called glioblastoma (GBM) may represent a new treatment strategy. In this study, aromatase inhibition was achieved using third generation inhibitor, Letrozole, encapsulated within the core of biodegradable poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs). PLGA-NPs were conjugated to human/mouse chimeric anti-GD2 antibody ch14.18/CHO, enabling specific targeting of GD2-positive GBM cells. Treatment of primary and recurrent patient-derived GBM cells with free-Letrozole (0.1 μM) led to significant decrease in cell proliferation and migration; in addition to reduced spheroid formation. Anti-GD2-ch14.18/CHO-NPs displayed specific targeting of GBM cells in colorectal-glioblastoma co-culture, with subsequent reduction in GBM cell numbers when treated with anti-GD2-ch14.18-PLGA-Let-NPs in combination with temozolomide. As miR-191 is an estrogen responsive microRNA, its expression, fluctuation and role in Letrozole treated GBM cells was evaluated, where treatment with premiR-191 was capable of rescuing the reduced proliferative phenotype induced by aromatase inhibitor. The repurposing and targeted delivery of Letrozole for the treatment of GBM, with the potential role of miR-191 identified, provides novel avenues for target assessment in this aggressive brain cancer.

Original languageEnglish (US)
Pages (from-to)16605-16620
Number of pages16
JournalOncotarget
Volume8
Issue number10
DOIs
StatePublished - 2017
Externally publishedYes

Fingerprint

letrozole
Aromatase Inhibitors
Glioblastoma
Nanoparticles
Aromatase
Neoplasms
temozolomide
Brain Neoplasms
Estrogens
ch14.18 monoclonal antibody
Therapeutics
Coculture Techniques
MicroRNAs

Keywords

  • Aromatase inhibitor
  • Brain
  • Glioblastoma
  • MiRNA-191
  • Nanoparticles

ASJC Scopus subject areas

  • Oncology

Cite this

Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patientderived GBM tumor cells. / Tivnan, Amanda; Heilinger, Tatjana; Ramsey, Joanne M.; O'Connor, Gemma; Pokorny, Jenny L.; Sarkaria, Jann N; Stringer, Brett W.; Day, Bryan W.; Boyd, Andrew W.; Kim, Ella L.; Lode, Holger N.; Cryan, Sally Ann; Prehn, Jochen H M.

In: Oncotarget, Vol. 8, No. 10, 2017, p. 16605-16620.

Research output: Contribution to journalArticle

Tivnan, Amanda ; Heilinger, Tatjana ; Ramsey, Joanne M. ; O'Connor, Gemma ; Pokorny, Jenny L. ; Sarkaria, Jann N ; Stringer, Brett W. ; Day, Bryan W. ; Boyd, Andrew W. ; Kim, Ella L. ; Lode, Holger N. ; Cryan, Sally Ann ; Prehn, Jochen H M. / Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patientderived GBM tumor cells. In: Oncotarget. 2017 ; Vol. 8, No. 10. pp. 16605-16620.
@article{e0db22e9b8a24cefaf179071794347f1,
title = "Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patientderived GBM tumor cells",
abstract = "Aromatase is a critical enzyme in the irreversible conversion of androgens to oestrogens, with inhibition used clinically in hormone-dependent malignancies. We tested the hypothesis that targeted aromatase inhibition in an aggressive brain cancer called glioblastoma (GBM) may represent a new treatment strategy. In this study, aromatase inhibition was achieved using third generation inhibitor, Letrozole, encapsulated within the core of biodegradable poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs). PLGA-NPs were conjugated to human/mouse chimeric anti-GD2 antibody ch14.18/CHO, enabling specific targeting of GD2-positive GBM cells. Treatment of primary and recurrent patient-derived GBM cells with free-Letrozole (0.1 μM) led to significant decrease in cell proliferation and migration; in addition to reduced spheroid formation. Anti-GD2-ch14.18/CHO-NPs displayed specific targeting of GBM cells in colorectal-glioblastoma co-culture, with subsequent reduction in GBM cell numbers when treated with anti-GD2-ch14.18-PLGA-Let-NPs in combination with temozolomide. As miR-191 is an estrogen responsive microRNA, its expression, fluctuation and role in Letrozole treated GBM cells was evaluated, where treatment with premiR-191 was capable of rescuing the reduced proliferative phenotype induced by aromatase inhibitor. The repurposing and targeted delivery of Letrozole for the treatment of GBM, with the potential role of miR-191 identified, provides novel avenues for target assessment in this aggressive brain cancer.",
keywords = "Aromatase inhibitor, Brain, Glioblastoma, MiRNA-191, Nanoparticles",
author = "Amanda Tivnan and Tatjana Heilinger and Ramsey, {Joanne M.} and Gemma O'Connor and Pokorny, {Jenny L.} and Sarkaria, {Jann N} and Stringer, {Brett W.} and Day, {Bryan W.} and Boyd, {Andrew W.} and Kim, {Ella L.} and Lode, {Holger N.} and Cryan, {Sally Ann} and Prehn, {Jochen H M}",
year = "2017",
doi = "10.18632/oncotarget.15073",
language = "English (US)",
volume = "8",
pages = "16605--16620",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "10",

}

TY - JOUR

T1 - Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patientderived GBM tumor cells

AU - Tivnan, Amanda

AU - Heilinger, Tatjana

AU - Ramsey, Joanne M.

AU - O'Connor, Gemma

AU - Pokorny, Jenny L.

AU - Sarkaria, Jann N

AU - Stringer, Brett W.

AU - Day, Bryan W.

AU - Boyd, Andrew W.

AU - Kim, Ella L.

AU - Lode, Holger N.

AU - Cryan, Sally Ann

AU - Prehn, Jochen H M

PY - 2017

Y1 - 2017

N2 - Aromatase is a critical enzyme in the irreversible conversion of androgens to oestrogens, with inhibition used clinically in hormone-dependent malignancies. We tested the hypothesis that targeted aromatase inhibition in an aggressive brain cancer called glioblastoma (GBM) may represent a new treatment strategy. In this study, aromatase inhibition was achieved using third generation inhibitor, Letrozole, encapsulated within the core of biodegradable poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs). PLGA-NPs were conjugated to human/mouse chimeric anti-GD2 antibody ch14.18/CHO, enabling specific targeting of GD2-positive GBM cells. Treatment of primary and recurrent patient-derived GBM cells with free-Letrozole (0.1 μM) led to significant decrease in cell proliferation and migration; in addition to reduced spheroid formation. Anti-GD2-ch14.18/CHO-NPs displayed specific targeting of GBM cells in colorectal-glioblastoma co-culture, with subsequent reduction in GBM cell numbers when treated with anti-GD2-ch14.18-PLGA-Let-NPs in combination with temozolomide. As miR-191 is an estrogen responsive microRNA, its expression, fluctuation and role in Letrozole treated GBM cells was evaluated, where treatment with premiR-191 was capable of rescuing the reduced proliferative phenotype induced by aromatase inhibitor. The repurposing and targeted delivery of Letrozole for the treatment of GBM, with the potential role of miR-191 identified, provides novel avenues for target assessment in this aggressive brain cancer.

AB - Aromatase is a critical enzyme in the irreversible conversion of androgens to oestrogens, with inhibition used clinically in hormone-dependent malignancies. We tested the hypothesis that targeted aromatase inhibition in an aggressive brain cancer called glioblastoma (GBM) may represent a new treatment strategy. In this study, aromatase inhibition was achieved using third generation inhibitor, Letrozole, encapsulated within the core of biodegradable poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs). PLGA-NPs were conjugated to human/mouse chimeric anti-GD2 antibody ch14.18/CHO, enabling specific targeting of GD2-positive GBM cells. Treatment of primary and recurrent patient-derived GBM cells with free-Letrozole (0.1 μM) led to significant decrease in cell proliferation and migration; in addition to reduced spheroid formation. Anti-GD2-ch14.18/CHO-NPs displayed specific targeting of GBM cells in colorectal-glioblastoma co-culture, with subsequent reduction in GBM cell numbers when treated with anti-GD2-ch14.18-PLGA-Let-NPs in combination with temozolomide. As miR-191 is an estrogen responsive microRNA, its expression, fluctuation and role in Letrozole treated GBM cells was evaluated, where treatment with premiR-191 was capable of rescuing the reduced proliferative phenotype induced by aromatase inhibitor. The repurposing and targeted delivery of Letrozole for the treatment of GBM, with the potential role of miR-191 identified, provides novel avenues for target assessment in this aggressive brain cancer.

KW - Aromatase inhibitor

KW - Brain

KW - Glioblastoma

KW - MiRNA-191

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85014715609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014715609&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.15073

DO - 10.18632/oncotarget.15073

M3 - Article

VL - 8

SP - 16605

EP - 16620

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 10

ER -